Epitope-Independent Pretargeted Therapy of Cancers Using Bacteria
AssigneeUniversity of Cincinnati
InventorsNalinikanth KOTAGIRI, Nabil SIDDIQUI
Life of this patent
Estimating the term…
Abstract
A genetically engineered Escherichia coli Nissle 1917 bacterium is provided. The genetically engineered bacterium comprises an overexpressed number of FyuA receptors. In one embodiment, the genetically engineered bacterium comprises the nucleotide sequence shown in SEQ ID NO:1. In another embodiment, the genetically engineered bacterium further comprises cell-associated 67Cu complexed to yersiniabactin (67Cu-YbT). In one embodiment, the genetically engineered bacterium further comprises cell-associated 64Cu complexed to yersiniabactin (64Cu-YbT).
Claims15
A genetically engineered Escherichia coli Nissle 1917 bacterium comprising an overexpressed number of FyuA receptors.
A method of providing targeted radionuclide therapy to subject with a tumor having cancer cells comprising administering to the subject a bacterium that has been genetically engineered to have an overexpressed number of FyuA receptors;
- wherein the bacterium further comprises at least one cell-associated copper radioisotope;
- and further, wherein the bacterium populates the tumor and delivers a cytotoxic dose of the radioisotope to the cancer cells.
A method of imaging a tumor in subject with a tumor comprising administering to the subject a bacterium that has been genetically engineered to have an overexpressed number of FyuA receptors;
- wherein the bacterium further comprises at least one cell-associated copper radioisotope;
- wherein the bacterium populates the tumor, and further, wherein positron emission tomography (PET) imaging is conducted on the subject after the bacterium has populated the tumor.
Dependencies are inferred from the claim text.